查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1467745

2024-2032 年非酒精性脂肪性肝炎市場（按藥物類型、疾病原因、銷售管道、最終用戶和地區）

Non-Alcoholic Steatohepatitis Market by Drug Type, Disease Cause, Sales Channel, End User, and Region 2024-2032
出版日期: | 出版商: IMARC | 英文 137 Pages | 商品交期: 2-3個工作天內

價格

2023年全球非酒精性脂肪性肝炎（NASH）IMARC Group規模達16億美元。 。 NASH 盛行率不斷上升、人們對早期診斷和治療的認知不斷提高，以及人工智慧 (AI) 和機器學習 (ML) 技術的融合是推動市場發展的一些關鍵因素。

非酒精性脂肪性肝炎（NASH）是指由胰島素阻抗、過重和代謝症候群引起的進行性非酒精性脂肪肝病（NAFLD）。其症狀包括疲勞無力、體重減輕、黃疸、皮膚搔癢、蜘蛛網狀靜脈、肝臟腫大、注意力不集中、積液以及腹部不適（例如疼痛和腫脹）。它可以透過多種技術進行診斷，例如體檢、血液檢查、肝臟活體組織切片、磁振造影 (MRI)、超音波和電腦斷層掃描 (CT) 掃描。 NASH 治療包括藥物治療、肝臟移植和各種生活方式的改變，例如定期運動和健康飲食。這些治療方法有助於減少肝臟脂肪堆積、改善肝功能、減少發炎並最大限度地減少肝損傷。它們還可以提高患者的生活品質，改善長期結果，並可以更好地管理其他健康問題，例如肥胖和高血壓。

非酒精性脂肪性肝炎 (NASH) 市場趨勢：

由於遺傳、久坐的生活方式、不健康的飲食習慣、肥胖和第 2 型糖尿病，NASH 盛行率不斷上升，是推動市場成長的關鍵因素之一。與此一致，NASH治療被患者廣泛採用，以緩解症狀、延長壽命、防止過早死亡、改善肝臟健康並促進整體福祉，這反過來又推動了市場成長。此外，大眾對早期診斷和治療NASH 的認知不斷提高，以減少醫療費用，消除肝臟移植的需要，並預防未來的併發症，如高血壓、心血管疾病(CVD)、癌症、肝硬化和肝臟疾病。此外，利用非侵入性成像技術（例如 MRI 和瞬時彈性成像 (TE)）來監測和診斷 NASH，從而提高患者的舒適度、提高依從性、降低併發症風險並改善臨床結果，對市場成長產生積極影響。除此之外，人工智慧（AI）和機器學習（ML）的整合來開發個人化治療、提高診斷準確性和預測疾病進展也有利於市場成長。此外，政府實施的各種旨在提供高品質治療和支持先進療法開發的措施正在推動市場成長。其他因素，包括老年人口的增加、醫療保健支出的增加、廣泛的研發 (R&D) 活動、醫療保健行業的顯著成長以及對非侵入性治療方案的需求不斷增加，預計將推動市場成長。

本報告回答的關鍵問題

  • 全球非酒精性脂肪性肝炎（NASH）市場有多大？
  • 2024-2032年全球非酒精性脂肪性肝炎（NASH）市場的預期成長率為何？
  • 推動全球非酒精性脂肪性肝炎（NASH）市場的關鍵因素是什麼？
  • COVID-19 對全球非酒精性脂肪性肝炎 (NASH) 市場有何影響？
  • 根據藥物類型，全球非酒精性脂肪性肝炎 (NASH) 市場的細分如何？
  • 根據疾病原因，全球非酒精性脂肪性肝炎 (NASH) 市場的細分如何？
  • 根據銷售管道，全球非酒精性脂肪性肝炎 (NASH) 市場的詳細情形如何？
  • 基於最終用戶的全球非酒精性脂肪性肝炎 (NASH) 市場的詳細情形如何？
  • 全球非酒精性脂肪性肝炎（NASH）市場的關鍵地區有哪些？
  • 誰是全球非酒精性脂肪性肝炎 (NASH) 市場的主要參與者/公司？

目錄

第1章：前言

第 2 章：範圍與方法

  • 研究目的
  • 利害關係人
  • 資料來源
    • 主要資源
    • 二手資料
  • 市場預測
    • 自下而上的方法
    • 自上而下的方法
  • 預測方法

第 3 章：執行摘要

第 4 章：簡介

  • 概述
  • 主要行業趨勢

第 5 章：全球非酒精性脂肪性肝炎 (NASH) 市場

  • 市場概況
  • 市場業績
  • COVID-19 的影響
  • 市場預測

第 6 章：市場區隔：依藥物類型

  • 維生素E和吡格列酮
    • 市場走向
    • 市場預測
  • 奧卡利瓦
    • 市場走向
    • 市場預測
  • 埃拉菲布拉諾
    • 市場走向
    • 市場預測
  • 塞隆塞提布
    • 市場走向
    • 市場預測
  • 塞尼奇韋羅
    • 市場走向
    • 市場預測
  • 其他
    • 市場走向
    • 市場預測

第 7 章：市場區隔：依疾病原因

  • 高血壓
    • 市場走向
    • 市場預測
  • 心臟病
    • 市場走向
    • 市場預測
  • 高血脂
    • 市場走向
    • 市場預測
  • 2型糖尿病
    • 市場走向
    • 市場預測
  • 肥胖
    • 市場走向
    • 市場預測

第 8 章：市場區隔：依銷售管道

  • 醫院藥房
    • 市場走向
    • 市場預測
  • 線上提供者
    • 市場走向
    • 市場預測
  • 零售藥房
    • 市場走向
    • 市場預測

第 9 章：市場區隔：按最終用戶

  • 醫院
    • 市場走向
    • 市場預測
  • 診所
    • 市場走向
    • 市場預測
  • 家庭護理設置
    • 市場走向
    • 市場預測

第 10 章：市場區隔：按地區

  • 北美洲
    • 美國
      • 市場走向
      • 市場預測
    • 加拿大
      • 市場走向
      • 市場預測
  • 亞太
    • 中國
      • 市場走向
      • 市場預測
    • 日本
      • 市場走向
      • 市場預測
    • 印度
      • 市場走向
      • 市場預測
    • 韓國
      • 市場走向
      • 市場預測
    • 澳洲
      • 市場走向
      • 市場預測
    • 印尼
      • 市場走向
      • 市場預測
    • 其他
      • 市場走向
      • 市場預測
  • 歐洲
    • 德國
      • 市場走向
      • 市場預測
    • 法國
      • 市場走向
      • 市場預測
    • 英國
      • 市場走向
      • 市場預測
    • 義大利
      • 市場走向
      • 市場預測
    • 西班牙
      • 市場走向
      • 市場預測
    • 俄羅斯
      • 市場走向
      • 市場預測
    • 其他
      • 市場走向
      • 市場預測
  • 拉丁美洲
    • 巴西
      • 市場走向
      • 市場預測
    • 墨西哥
      • 市場走向
      • 市場預測
    • 其他
      • 市場走向
      • 市場預測
  • 中東和非洲
    • 市場走向
    • 市場細分：按國家/地區
    • 市場預測

第 11 章：促進因素、限制與機會

  • 概述
  • 促進要素
  • 限制
  • 機會

第 12 章：價值鏈分析

第 13 章：波特五力分析

  • 概述
  • 買家的議價能力
  • 供應商的議價能力
  • 競爭程度
  • 新進入者的威脅
  • 替代品的威脅

第 14 章：價格分析

第15章：競爭格局

  • 市場結構
  • 關鍵參與者
  • 關鍵參與者簡介
    • Algernon Pharmaceuticals
    • Galmed Pharmaceuticals Ltd
    • Intercept Pharmaceuticals Inc.
    • Zydus Lifesciences Limited
Product Code: SR112024A7397

The global non-alcoholic steatohepatitis (NASH) market size reached US$ 1.6 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 11.5 Billion by 2032, exhibiting a growth rate (CAGR) of 24.18% during 2024-2032. The rising prevalence of NASH, increasing awareness regarding early diagnosis and treatments, and the integration of artificial intelligence (AI) and machine learning (ML) technologies represent some of the key factors driving the market.

Non-alcoholic steatohepatitis (NASH) refers to a progressive non-alcoholic fatty liver disease (NAFLD) caused by insulin resistance, overweight, and metabolic syndrome. Its symptoms involve fatigue and weakness, weight loss, jaundice, itchy skin, spider veins, enlarged liver, lack of concentration, fluid accumulation, and abdominal discomfort, such as pain and swelling. It is diagnosed through multiple techniques, such as physical examination, blood test, liver biopsy, magnetic resonance imaging (MRI), ultrasound, and computed tomography (CT) scan. NASH treatment includes medication, liver transplant, and various lifestyle modifications, such as regular exercise, and healthy diets. These treatment methods aid in reducing liver fat accumulation, improving liver function, reducing inflammation, and minimizing liver damage. They also enhance patients' quality of life, improve long-term outcomes, and allow better management of other health problems, such as obesity and high blood pressure.

Non-Alcoholic Steatohepatitis (NASH) Market Trends:

The rising prevalence of NASH due to genetics, sedentary lifestyle, unhealthy eating habits, obesity, and type 2 diabetes is one of the key factors driving the market growth. In line with this, NASH treatments are widely adopted by patients to alleviate symptoms, increase lifespan, prevent premature death, improve liver health, and promote overall well-being, which in turn is providing a thrust to the market growth. Furthermore, the increasing awareness among the masses regarding early diagnosis and treatment of NASH to reduce healthcare expenses, eliminate the need for liver transplants, and prevent future complications, such as high blood pressure, cardiovascular diseases (CVDs), cancer, cirrhosis, and liver failure is providing an impetus to the market growth. Additionally, the utilization of non-invasive imaging techniques to monitor and diagnose NASH, such as MRI and transient elastography (TE), which, in turn, enhances patients' comfort, increases compliance, reduces the risk of complications, and improves clinical outcomes, is positively influencing the market growth. Besides this, the integration of artificial intelligence (AI) and machine learning (ML) to develop personalized treatments, improve diagnosis accuracy, and predict disease progression is favoring the market growth. Moreover, the implementation of various government initiatives to provide access to high-quality treatment and support the development of advanced therapeutics is propelling the market growth. Other factors, including the rising geriatric population, increasing healthcare expenditure, extensive research and development (R&D) activities, significant growth in the healthcare industry, and the increasing demand for non-invasive treatment options, are anticipated to drive the market growth.

Key Market Segmentation:

IMARC Group provides an analysis of the key trends in each segment of the global non-alcoholic steatohepatitis (NASH) market, along with forecasts at the global, regional, and country levels from 2024-2032. Our report has categorized the market based on drug type, disease cause, sales channel, and end user.

Drug Type Insights:

Vitamin E and Pioglitazone

Ocaliva

Elafibranor

Selonsertib

Cenicriviroc

Others

The report has provided a detailed breakup and analysis of the non-alcoholic steatohepatitis (NASH) market based on the drug type. This includes Vitamin E and Pioglitazone, Ocaliva, Elafibranor, Selonsertib, Cenicriviroc, and others. According to the report, vitamin E and pioglitazone represented the largest segment.

Disease Cause Insights:

Hypertension

Heart Disease

High Blood Lipid

Type 2 Diabetes

Obesity

A detailed breakup and analysis of the non-alcoholic steatohepatitis (NASH) market based on the disease cause has also been provided in the report. This includes hypertension, heart disease, high blood lipid, type 2 diabetes, and obesity. According to the report, obesity accounted for the largest market share.

Sales Channel Insights:

Hospital Pharmacy

Online Providers

Retail Pharmacy

A detailed breakup and analysis of the non-alcoholic steatohepatitis (NASH) market based on the sales channel has also been provided in the report. This includes hospital pharmacy, online providers, and retail pharmacy. According to the report, retail pharmacy accounted for the largest market share.

End User Insights:

Hospitals

Clinics

Homecare Settings

A detailed breakup and analysis of the non-alcoholic steatohepatitis (NASH) market based on the end user has also been provided in the report. This includes hospitals, clinics, and homecare settings. According to the report, clinics accounted for the largest market share.

Regional Insights:

North America

United States

Canada

Europe

Germany

France

United Kingdom

Italy

Spain

Russia

Others

Asia Pacific

China

Japan

India

South Korea

Australia

Indonesia

Others

Latin America

Brazil

Mexico

Others

Middle East and Africa

The report has also provided a comprehensive analysis of all the major regional markets, which include North America (the United States and Canada); Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Latin America (Brazil, Mexico, and others); and the Middle East and Africa. According to the report, North America was the largest market for non-alcoholic steatohepatitis (NASH). Some of the factors driving the North America non-alcoholic steatohepatitis (NASH) market included the rising prevalence of NASH, increasing government initiatives, and rapid technological advancements.

Competitive Landscape:

The report has also provided a comprehensive analysis of the competitive landscape in the global non-alcoholic steatohepatitis (NASH) market. Detailed profiles of all major companies have also been provided. Some of the companies covered include Algernon Pharmaceuticals, Galmed Pharmaceuticals Ltd, Intercept Pharmaceuticals Inc., Zydus Lifesciences Limited, etc. Kindly note that this only represents a partial list of companies, and the complete list has been provided in the report.

Key Questions Answered in This Report

  • 1. How big is the global Non-Alcoholic Steatohepatitis (NASH) market?
  • 2. What is the expected growth rate of the global Non-Alcoholic Steatohepatitis (NASH) market during 2024-2032?
  • 3. What are the key factors driving the global Non-Alcoholic Steatohepatitis (NASH) market?
  • 4. What has been the impact of COVID-19 on the global Non-Alcoholic Steatohepatitis (NASH) market?
  • 5. What is the breakup of the global Non-Alcoholic Steatohepatitis (NASH) market based on the drug type?
  • 6. What is the breakup of the global Non-Alcoholic Steatohepatitis (NASH) market based on the disease cause?
  • 7. What is the breakup of the global Non-Alcoholic Steatohepatitis (NASH) market based on the sales channel?
  • 8. What is the breakup of the global Non-Alcoholic Steatohepatitis (NASH) market based on the end user?
  • 9. What are the key regions in the global Non-Alcoholic Steatohepatitis (NASH) market?
  • 10. Who are the key players/companies in the global Non-Alcoholic Steatohepatitis (NASH) market?

Table of Contents

1 Preface

2 Scope and Methodology

  • 2.1 Objectives of the Study
  • 2.2 Stakeholders
  • 2.3 Data Sources
    • 2.3.1 Primary Sources
    • 2.3.2 Secondary Sources
  • 2.4 Market Estimation
    • 2.4.1 Bottom-Up Approach
    • 2.4.2 Top-Down Approach
  • 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

  • 4.1 Overview
  • 4.2 Key Industry Trends

5 Global Non-Alcoholic Steatohepatitis (NASH) Market

  • 5.1 Market Overview
  • 5.2 Market Performance
  • 5.3 Impact of COVID-19
  • 5.4 Market Forecast

6 Market Breakup by Drug Type

  • 6.1 Vitamin E and Pioglitazone
    • 6.1.1 Market Trends
    • 6.1.2 Market Forecast
  • 6.2 Ocaliva
    • 6.2.1 Market Trends
    • 6.2.2 Market Forecast
  • 6.3 Elafibranor
    • 6.3.1 Market Trends
    • 6.3.2 Market Forecast
  • 6.4 Selonsertib
    • 6.4.1 Market Trends
    • 6.4.2 Market Forecast
  • 6.5 Cenicriviroc
    • 6.5.1 Market Trends
    • 6.5.2 Market Forecast
  • 6.6 Others
    • 6.6.1 Market Trends
    • 6.6.2 Market Forecast

7 Market Breakup by Disease Cause

  • 7.1 Hypertension
    • 7.1.1 Market Trends
    • 7.1.2 Market Forecast
  • 7.2 Heart Disease
    • 7.2.1 Market Trends
    • 7.2.2 Market Forecast
  • 7.3 High Blood Lipid
    • 7.3.1 Market Trends
    • 7.3.2 Market Forecast
  • 7.4 Type 2 Diabetes
    • 7.4.1 Market Trends
    • 7.4.2 Market Forecast
  • 7.5 Obesity
    • 7.5.1 Market Trends
    • 7.5.2 Market Forecast

8 Market Breakup by Sales Channel

  • 8.1 Hospital Pharmacy
    • 8.1.1 Market Trends
    • 8.1.2 Market Forecast
  • 8.2 Online Providers
    • 8.2.1 Market Trends
    • 8.2.2 Market Forecast
  • 8.3 Retail Pharmacy
    • 8.3.1 Market Trends
    • 8.3.2 Market Forecast

9 Market Breakup by End User

  • 9.1 Hospitals
    • 9.1.1 Market Trends
    • 9.1.2 Market Forecast
  • 9.2 Clinics
    • 9.2.1 Market Trends
    • 9.2.2 Market Forecast
  • 9.3 Homecare Settings
    • 9.3.1 Market Trends
    • 9.3.2 Market Forecast

10 Market Breakup by Region

  • 10.1 North America
    • 10.1.1 United States
      • 10.1.1.1 Market Trends
      • 10.1.1.2 Market Forecast
    • 10.1.2 Canada
      • 10.1.2.1 Market Trends
      • 10.1.2.2 Market Forecast
  • 10.2 Asia-Pacific
    • 10.2.1 China
      • 10.2.1.1 Market Trends
      • 10.2.1.2 Market Forecast
    • 10.2.2 Japan
      • 10.2.2.1 Market Trends
      • 10.2.2.2 Market Forecast
    • 10.2.3 India
      • 10.2.3.1 Market Trends
      • 10.2.3.2 Market Forecast
    • 10.2.4 South Korea
      • 10.2.4.1 Market Trends
      • 10.2.4.2 Market Forecast
    • 10.2.5 Australia
      • 10.2.5.1 Market Trends
      • 10.2.5.2 Market Forecast
    • 10.2.6 Indonesia
      • 10.2.6.1 Market Trends
      • 10.2.6.2 Market Forecast
    • 10.2.7 Others
      • 10.2.7.1 Market Trends
      • 10.2.7.2 Market Forecast
  • 10.3 Europe
    • 10.3.1 Germany
      • 10.3.1.1 Market Trends
      • 10.3.1.2 Market Forecast
    • 10.3.2 France
      • 10.3.2.1 Market Trends
      • 10.3.2.2 Market Forecast
    • 10.3.3 United Kingdom
      • 10.3.3.1 Market Trends
      • 10.3.3.2 Market Forecast
    • 10.3.4 Italy
      • 10.3.4.1 Market Trends
      • 10.3.4.2 Market Forecast
    • 10.3.5 Spain
      • 10.3.5.1 Market Trends
      • 10.3.5.2 Market Forecast
    • 10.3.6 Russia
      • 10.3.6.1 Market Trends
      • 10.3.6.2 Market Forecast
    • 10.3.7 Others
      • 10.3.7.1 Market Trends
      • 10.3.7.2 Market Forecast
  • 10.4 Latin America
    • 10.4.1 Brazil
      • 10.4.1.1 Market Trends
      • 10.4.1.2 Market Forecast
    • 10.4.2 Mexico
      • 10.4.2.1 Market Trends
      • 10.4.2.2 Market Forecast
    • 10.4.3 Others
      • 10.4.3.1 Market Trends
      • 10.4.3.2 Market Forecast
  • 10.5 Middle East and Africa
    • 10.5.1 Market Trends
    • 10.5.2 Market Breakup by Country
    • 10.5.3 Market Forecast

11 Drivers, Restraints, and Opportunities

  • 11.1 Overview
  • 11.2 Drivers
  • 11.3 Restraints
  • 11.4 Opportunities

12 Value Chain Analysis

13 Porters Five Forces Analysis

  • 13.1 Overview
  • 13.2 Bargaining Power of Buyers
  • 13.3 Bargaining Power of Suppliers
  • 13.4 Degree of Competition
  • 13.5 Threat of New Entrants
  • 13.6 Threat of Substitutes

14 Price Analysis

15 Competitive Landscape

  • 15.1 Market Structure
  • 15.2 Key Players
  • 15.3 Profiles of Key Players
    • 15.3.1 Algernon Pharmaceuticals
      • 15.3.1.1 Company Overview
      • 15.3.1.2 Product Portfolio
    • 15.3.2 Galmed Pharmaceuticals Ltd
      • 15.3.2.1 Company Overview
      • 15.3.2.2 Product Portfolio
      • 15.3.2.3 Financials
    • 15.3.3 Intercept Pharmaceuticals Inc.
      • 15.3.3.1 Company Overview
      • 15.3.3.2 Product Portfolio
      • 15.3.3.3 Financials
      • 15.3.3.4 SWOT Analysis
    • 15.3.4 Zydus Lifesciences Limited
      • 15.3.4.1 Company Overview
      • 15.3.4.2 Product Portfolio
      • 15.3.4.3 Financials
      • 15.3.4.4 SWOT Analysis

Kindly note that this only represents a partial list of companies, and the complete list has been provided in the report.

List of Figures

  • Figure 1: Global: Non-Alcoholic Steatohepatitis Market: Major Drivers and Challenges
  • Figure 2: Global: Non-Alcoholic Steatohepatitis Market: Sales Value (in Billion US$), 2018-2023
  • Figure 3: Global: Non-Alcoholic Steatohepatitis Market Forecast: Sales Value (in Billion US$), 2024-2032
  • Figure 4: Global: Non-Alcoholic Steatohepatitis Market: Breakup by Drug Type (in %), 2023
  • Figure 5: Global: Non-Alcoholic Steatohepatitis Market: Breakup by Disease Cause (in %), 2023
  • Figure 6: Global: Non-Alcoholic Steatohepatitis Market: Breakup by Sales Channel (in %), 2023
  • Figure 7: Global: Non-Alcoholic Steatohepatitis Market: Breakup by End User (in %), 2023
  • Figure 8: Global: Non-Alcoholic Steatohepatitis Market: Breakup by Region (in %), 2023
  • Figure 9: Global: Non-Alcoholic Steatohepatitis (Vitamin E and Pioglitazone) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 10: Global: Non-Alcoholic Steatohepatitis (Vitamin E and Pioglitazone) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 11: Global: Non-Alcoholic Steatohepatitis (Ocaliva) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 12: Global: Non-Alcoholic Steatohepatitis (Ocaliva) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 13: Global: Non-Alcoholic Steatohepatitis (Elafibranor) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 14: Global: Non-Alcoholic Steatohepatitis (Elafibranor) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 15: Global: Non-Alcoholic Steatohepatitis (Selonsertib) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 16: Global: Non-Alcoholic Steatohepatitis (Selonsertib) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 17: Global: Non-Alcoholic Steatohepatitis (Cenicriviroc) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 18: Global: Non-Alcoholic Steatohepatitis (Cenicriviroc) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 19: Global: Non-Alcoholic Steatohepatitis (Other Drug Types) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 20: Global: Non-Alcoholic Steatohepatitis (Other Drug Types) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 21: Global: Non-Alcoholic Steatohepatitis (Hypertension) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 22: Global: Non-Alcoholic Steatohepatitis (Hypertension) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 23: Global: Non-Alcoholic Steatohepatitis (Heart Disease) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 24: Global: Non-Alcoholic Steatohepatitis (Heart Disease) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 25: Global: Non-Alcoholic Steatohepatitis (High Blood Lipid) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 26: Global: Non-Alcoholic Steatohepatitis (High Blood Lipid) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 27: Global: Non-Alcoholic Steatohepatitis (Type 2 Diabetes) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 28: Global: Non-Alcoholic Steatohepatitis (Type 2 Diabetes) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 29: Global: Non-Alcoholic Steatohepatitis (Obesity) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 30: Global: Non-Alcoholic Steatohepatitis (Obesity) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 31: Global: Non-Alcoholic Steatohepatitis (Hospital Pharmacy) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 32: Global: Non-Alcoholic Steatohepatitis (Hospital Pharmacy) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 33: Global: Non-Alcoholic Steatohepatitis (Online Providers) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 34: Global: Non-Alcoholic Steatohepatitis (Online Providers) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 35: Global: Non-Alcoholic Steatohepatitis (Retail Pharmacy) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 36: Global: Non-Alcoholic Steatohepatitis (Retail Pharmacy) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 37: Global: Non-Alcoholic Steatohepatitis (Hospitals) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 38: Global: Non-Alcoholic Steatohepatitis (Hospitals) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 39: Global: Non-Alcoholic Steatohepatitis (Clinics) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 40: Global: Non-Alcoholic Steatohepatitis (Clinics) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 41: Global: Non-Alcoholic Steatohepatitis (Homecare Settings) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 42: Global: Non-Alcoholic Steatohepatitis (Homecare Settings) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 43: North America: Non-Alcoholic Steatohepatitis Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 44: North America: Non-Alcoholic Steatohepatitis Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 45: United States: Non-Alcoholic Steatohepatitis Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 46: United States: Non-Alcoholic Steatohepatitis Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 47: Canada: Non-Alcoholic Steatohepatitis Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 48: Canada: Non-Alcoholic Steatohepatitis Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 49: Asia-Pacific: Non-Alcoholic Steatohepatitis Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 50: Asia-Pacific: Non-Alcoholic Steatohepatitis Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 51: China: Non-Alcoholic Steatohepatitis Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 52: China: Non-Alcoholic Steatohepatitis Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 53: Japan: Non-Alcoholic Steatohepatitis Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 54: Japan: Non-Alcoholic Steatohepatitis Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 55: India: Non-Alcoholic Steatohepatitis Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 56: India: Non-Alcoholic Steatohepatitis Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 57: South Korea: Non-Alcoholic Steatohepatitis Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 58: South Korea: Non-Alcoholic Steatohepatitis Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 59: Australia: Non-Alcoholic Steatohepatitis Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 60: Australia: Non-Alcoholic Steatohepatitis Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 61: Indonesia: Non-Alcoholic Steatohepatitis Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 62: Indonesia: Non-Alcoholic Steatohepatitis Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 63: Others: Non-Alcoholic Steatohepatitis Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 64: Others: Non-Alcoholic Steatohepatitis Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 65: Europe: Non-Alcoholic Steatohepatitis Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 66: Europe: Non-Alcoholic Steatohepatitis Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 67: Germany: Non-Alcoholic Steatohepatitis Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 68: Germany: Non-Alcoholic Steatohepatitis Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 69: France: Non-Alcoholic Steatohepatitis Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 70: France: Non-Alcoholic Steatohepatitis Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 71: United Kingdom: Non-Alcoholic Steatohepatitis Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 72: United Kingdom: Non-Alcoholic Steatohepatitis Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 73: Italy: Non-Alcoholic Steatohepatitis Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 74: Italy: Non-Alcoholic Steatohepatitis Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 75: Spain: Non-Alcoholic Steatohepatitis Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 76: Spain: Non-Alcoholic Steatohepatitis Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 77: Russia: Non-Alcoholic Steatohepatitis Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 78: Russia: Non-Alcoholic Steatohepatitis Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 79: Others: Non-Alcoholic Steatohepatitis Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 80: Others: Non-Alcoholic Steatohepatitis Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 81: Latin America: Non-Alcoholic Steatohepatitis Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 82: Latin America: Non-Alcoholic Steatohepatitis Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 83: Brazil: Non-Alcoholic Steatohepatitis Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 84: Brazil: Non-Alcoholic Steatohepatitis Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 85: Mexico: Non-Alcoholic Steatohepatitis Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 86: Mexico: Non-Alcoholic Steatohepatitis Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 87: Others: Non-Alcoholic Steatohepatitis Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 88: Others: Non-Alcoholic Steatohepatitis Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 89: Middle East and Africa: Non-Alcoholic Steatohepatitis Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 90: Middle East and Africa: Non-Alcoholic Steatohepatitis Market: Breakup by Country (in %), 2023
  • Figure 91: Middle East and Africa: Non-Alcoholic Steatohepatitis Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 92: Global: Non-Alcoholic Steatohepatitis Industry: Drivers, Restraints, and Opportunities
  • Figure 93: Global: Non-Alcoholic Steatohepatitis Industry: Value Chain Analysis
  • Figure 94: Global: Non-Alcoholic Steatohepatitis Industry: Porter's Five Forces Analysis

List of Tables

  • Table 1: Global: Non-Alcoholic Steatohepatitis Market: Key Industry Highlights, 2023 & 2032
  • Table 2: Global: Non-Alcoholic Steatohepatitis Market Forecast: Breakup by Drug Type (in Million US$), 2024-2032
  • Table 3: Global: Non-Alcoholic Steatohepatitis Market Forecast: Breakup by Disease Cause (in Million US$), 2024-2032
  • Table 4: Global: Non-Alcoholic Steatohepatitis Market Forecast: Breakup by Sales Channel (in Million US$), 2024-2032
  • Table 5: Global: Non-Alcoholic Steatohepatitis Market Forecast: Breakup by End User (in Million US$), 2024-2032
  • Table 6: Global: Non-Alcoholic Steatohepatitis Market Forecast: Breakup by Region (in Million US$), 2024-2032
  • Table 7: Global: Non-Alcoholic Steatohepatitis Market: Competitive Structure
  • Table 8: Global: Non-Alcoholic Steatohepatitis Market: Key Players